|
|
|
|
The PROMISE™ initiative consists of practical clinical information,
educational resources, and patient support tools—all focused on ensuring the
appropriate use of opioid analgesics and minimizing the inherent risks of misuse,
abuse, and diversion of these medications.
|
|
|
As a leader in the development and distribution of schedule II opioid analgesic medications,
Endo Pharmaceuticals is:
|
|
|
Committed to providing safe and effective opioid analgesic treatment options for patients suffering from
moderate-to-severe pain.
|
|
|
Dedicated to improving patient care and the appropriate clinical use of opioid analgesics through
access to treatment and a proactive approach to managing the potential risks inherent in opioid therapy.
|
|
|
Responsive with programs designed to promote appropriate and responsible use of opioid analgesic
medications and minimize the risks of misuse, abuse, and diversion.
|
|
|
PROMISE™ is one more example of Endo’s ongoing collaboration with patients, caregivers,
health care professionals and government agencies to ensure patients have appropriate medical
access to opioid analgesics for pain relief while also having the means to minimize the potential
inherent risks of these medications.
|
|
|
